AstraZeneca changes the name of its vaccine to improve its reputation

The antigen suffers another setback amid the controversy over its complications in the health of those vaccinated

Although AstraZeneca is one of the brands that has gained the most around the development of vaccines, the reality is that right now it is going through a reputation crisis after some countries warned about a possible relationship between some deaths and the application of the drug developed by this signature.

This issue has turned into a reputational crisis for the brand, so now the laboratory has decided to change the name of its vaccine in order to protect its reputation. In this way, the vaccine whose trademark is COVID-19 Vaccine AstraZeneca, has been commercially registered as Vaxzevria.

Iceland, Denmark and Norway were the first countries to stop inoculation with the vaccine created in collaboration with the University of Oxford until the European Medicines Agency (EMA) clarifies whether said medicine is related to the report of various cases of thrombi in patients who have received this vaccine in different countries of the European Union.

These decisions translate into a accreditation and trust problem around the aforementioned vaccine. As of March 9, only 22 cases of thromboembolic events had been reported among the three million people vaccinated with the AstraZeneca drug in the European Union.

In a statement, the brand stated that “patient safety is one of AstraZeneca's top priorities. The authorities have clear and strict standards of efficacy and safety when approving any new drug, and this also includes AstraZeneca's covid-19 vaccine. The safety of this vaccine has been extensively studied in Phase 3 clinical trials and peer-reviewed data confirm that the vaccine was generally well tolerated. "

After these suspensions were lifted, it was striking that in recent hours new countries announced the suspension of the AstraZeneca vaccine. The Canadian Ministry of Health announced the suspension of the use of the vaccine from the British-Swedish pharmaceutical AstraZeneca in children under 55 years of age as a precautionary measure and for safety.

Berlin and Munich also suspended the supply of the Astrazeneca Covid-19 vaccine for children under 60 years of age, in order to examine whether 30 cases of thrombosis could be related to the application of this drug.

Although the authorities insist on the validity and safety of these vaccines, the reality is that the brand wants to sharply distance itself from this reputational crisis that has already marked public opinion and that casts doubt on the confidence of one of the most promising vaccines .



					<div class="fb-comments" data-href="<?php the_permalink(); ?>" data-width="100%" data-numposts="5">&nbsp;</div>